Showing results (11-20 of 1,376) with videos related to
Sort By:
Pageof 138
Cardiovascular Diabetology|May 27, 2018
Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failureAtsushi Tanaka, Koichi NodeCardiovascular Diabetology|June 14, 2018
Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trialsAtsushi Tanaka, Koichi NodeDiabetology International|August 18, 2020
Promising roles of sodium-glucose cotransporter 2 inhibitors in heart failure prevention and treatmentAtsushi Tanaka, Koichi NodeCardiovascular Diabetology|February 12, 2021
Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitorsAtsushi Tanaka, Koichi NodeJournal of Cardiology|January 4, 2017
Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiologyAtsushi Tanaka, Koichi NodeHypertension Research : Official Journal of the Japanese Society of Hypertension|October 16, 2025
Risk management of cardiovascular disease in older patients with diabetesKosuke Sawami, Atsushi Tanaka, Koichi NodeSupportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 11, 2021
Clinical roles of vascular function assessment in cancer careKosuke Sawami, Atsushi Tanaka, Koichi NodeCardiovascular Diabetology|November 16, 2024
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectivesKosuke Sawami, Atsushi Tanaka, Koichi NodeCardiovascular Diabetology|September 6, 2022
Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonistsKosuke Sawami, Atsushi Tanaka, Koichi NodeHypertension Research : Official Journal of the Japanese Society of Hypertension|May 31, 2023
Recent understandings about hypertension management in type 2 diabetes: What are the roles of SGLT2 inhibitor, GLP-1 receptor agonist, and finerenone?Kosuke Sawami, Atsushi Tanaka, Koichi NodePageof 138